From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.
Insulin costs in the U.S. are notoriously high compared to the costs in other countries; the Rand Corporation, a public policy think tank, estimated that in 2018, the average list price for one vial of insulin in the U.S. was $98.70.
REI aims to have all cookware and apparel sold in its stores free of PFAS by fall of 2024. PFAS have been linked to cancer and other health problems.
The invasion of miners has contributed to the spread of malaria among the Yanomami, with devastating consequences
Like the “Berlin patient” and the “London patient” before him, the “Düsseldorf patient” received treatment for an acute blood disease and, in the process, was cured of HIV infection.
A painful, parasitic disease that once infected 3.5 million people per year is tantalizingly In 2022, just 12 cases were record worldwide.
Psychedelic medicine just crossed a historic threshold — Australia is now the first country to give psychiatrists a legal pathway to prescribe psilocybin and MDMA as regulated treatments for PTSD and treatment-resistant depression. For patients who have cycled through every available option without relief, that’s a genuinely new door opening. The decision followed thousands of public submissions and a growing body of clinical evidence, including a landmark New Zealand Journal of Medicine study on psilocybin’s efficacy. It shows that political barriers — not just scientific ones — can eventually fall when evidence and public pressure align.\n\n—\n\n**Word count: 95**
Fungal infections kill an estimated 1.6 million people every year, yet until now no vaccine has ever existed for any of the major culprits. Researchers at the University of Georgia have developed a single shot that trains the immune system to recognize all three deadliest fungal genera simultaneously — a feat never before demonstrated in peer-reviewed research. Crucially, it reduced illness and death in immunocompromised animals, the very people most at risk. For a disease category the WHO only recently recognized as a global emergency, this candidate offers the first real hope of prevention.\n\n*(Word count: 88)*
Morocco’s research foundation has developed cancer diagnostic tests made entirely in Africa—a breakthrough that promises to slash waiting times from weeks or months down to hours, and potentially cut costs in half. The leukemia test, already used on 400 patients, sidesteps the costly delays of importing kits from Europe or North America. Because results no longer need to travel abroad for interpretation, patients can receive treatment sooner when it matters most. This success builds on Morocco’s earlier COVID-19 test and positions African nations to control their own medical futures rather than depend on distant supply chains.\n\n**Word count: 95**
For decades researchers have been trying to develop a vaccine for the deadly respiratory disease. It looks like 2023 will be the landmark year where not only one, but possibly three different vaccines are approved.
Pfizer’s not-for-profit pricing pledge now spans all 500 of its medicines — including chemotherapy and oral cancer treatments — across 45 of the world’s lowest-income countries. That’s a major expansion of an accord the company launched in 2022, which originally covered only patented drugs. By including off-patent medicines too, Pfizer is acknowledging that even decades-old cancer treatments often remain out of reach where generic supply chains never took hold. For patients across much of sub-Saharan Africa and South Asia, where cancer and heart disease are rising fast, this could quietly move the floor on what’s possible. And when the world’s largest drugmaker makes a move this broad, the rest of the industry tends to notice.
